Real-world research on treatment patterns in Korea has highlighted the continuing high mortality in HCC, especially among the elevated AFP group, underlying a need for new treatments that can lengthen survival [90] Data were pooled in patients with elevated AFP from the REACH-2 and REACH trials, and an individual patient data meta-analysis was performed in the Asian (n = 291) and non-Asian (n = 251) patient subgroups [37]. The gene discussed is AFP; the disease is hepatocellular carcinoma.